The detection of psilocybin, the psychoactive compound in hallucinogenic mushrooms, through urinalysis is a topic of interest. Standard drug screenings typically do not include tests specifically designed to identify psilocybin or its metabolite, psilocin.
The relatively short half-life of psilocybin and psilocin in the body, coupled with the fact that they are not commonly tested for, means that detection windows are limited. This differs significantly from substances like cannabis or opioids, which are frequently included in standard drug panels and remain detectable for longer periods. The infrequency of testing stems from various factors, including cost, prevalence of use compared to other drugs, and the legal status in certain jurisdictions.